Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis

Bibliography

• Lublin FD. Clinical features and diagnosis of multiple sclerosis. Neurol Clin 2005;23(1):1-15
   PubMed Web of Science ®Google Scholar
• Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012;135(Pt 10):2952-61
   PubMed Web of Science ®Google Scholar
• Lugaresi A, di Ioia M, Travaglini D, et al. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat 2013;9:893-914
   PubMed Web of Science ®Google Scholar
• Calabresi P, Kieseier B, Arnold D, et al. ADVANCE phase 3 study of PEGylated interferon beta-1a for relapsing multiple sclerosis: patient baseline characteristics. Neurology 2012;78:P01.133
   Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013;73(6):705-13
   PubMed Web of Science ®Google Scholar
• Oh J, Calabresi PA. Emerging injectable therapies for multiple sclerosis. Lancet Neurol 2013;12(11):1115-26
   PubMed Web of Science ®Google Scholar
• Tanasescu R, Debouverie M, Pittion S, et al. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J Neurol 2004;251(6):762-3
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910
   PubMed Web of Science ®Google Scholar
• Rommer PS, Zettl UK, Kieseier B, et al. Requirement for safety monitoring for approved MS therapies - an overview. Clin Exp Immunol 2014;175(3):397-407
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366(20):1870-80
   PubMed Web of Science ®Google Scholar
• Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Therapeutics, technology assessment subcommittee of the American academy of N. Evidence report: the efficacy and safety of mitoxantrone (novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2010;74(18):1463-70
   PubMed Web of Science ®Google Scholar
• Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013;73(7):625-50
   PubMed Web of Science ®Google Scholar
• Tanasescu R, Evangelou N, Constantinescu CS. Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatr Dis Treat 2013;9:539-53
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098-107
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Pagani E, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2013. [Epub ahead of print]
   Google Scholar
• Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366(11):1000-9
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in Multiple sclerosis. Clin Neuropharmacol 2010;33(2):91-101
   PubMed Web of Science ®Google Scholar
• Zemann B, Kinzel B, Muller M, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006;107(4):1454-8
   PubMed Web of Science ®Google Scholar
• Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6(7):373-82
   PubMed Web of Science ®Google Scholar
• Mehling M, Lindberg RL, Kuhle J, et al. Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis. Mult Scler 2008;14:S234-S34
   Web of Science ®Google Scholar
• Buzzard KA, Broadley SA, Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci 2012;13(10):12665-709
   PubMed Web of Science ®Google Scholar
• Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P(1)) modulation. Proc Natl Acad Sci USA 2011;108(2):751-6
   PubMed Web of Science ®Google Scholar
• Lee CW, Choi JW, Chun J. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res 2010;33(10):1567-74
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. New Engl J Med 2006;355(11):1124-40
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder RL, Hartmann S, et al. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J Clin Pharmacol 2006;46(2):149-56
   PubMed Web of Science ®Google Scholar
• Meno-Tetang GM, Li H, Mis S, et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab Dispos 2006;34(9):1480-7
   PubMed Web of Science ®Google Scholar
• Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323(2):469-75
   PubMed Web of Science ®Google Scholar
• Horga A, Montalban X. FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev Neurother 2008;8(5):699-714
   PubMedGoogle Scholar
• Kovarik JM, Schmouder RL, Wang SY, et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol 2005;45(4):446-52
   PubMed Web of Science ®Google Scholar
• Spiegel S, Cuvillier O, Edsall L, et al. Roles of sphingosine-1-phosphate in cell growth, differentiation, and death. Biochemistry (Mosc) 1998;63(1):69-73
   PubMed Web of Science ®Google Scholar
• Spiegel S, Cuvillier O, Edsall LC, et al. Sphingosine-1-phosphate in cell growth and cell death. Ann NY Acad Sci 1998;845:11-18
   PubMed Web of Science ®Google Scholar
• Hu W, Mahavadi S, Huang J, et al. Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection. Am J Physiol Gastrointest Liver Physiol 2006;291(4):G605-10
   PubMed Web of Science ®Google Scholar
• Lee CW, Choi JW, Chun J. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis. Arch Pharm Res 2010;33(10):1567-74
   PubMed Web of Science ®Google Scholar
• Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010;33(2):91-101
   PubMed Web of Science ®Google Scholar
• Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann Neurol 2011;69(5):759-77
   PubMed Web of Science ®Google Scholar
• Mehling M, Johnson TA, Antel J, et al. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 2011;76(8 Suppl 3):S20-7
   PubMed Web of Science ®Google Scholar
• Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71(16):1261-7
   PubMed Web of Science ®Google Scholar
• Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291(5512):2413-17
   PubMed Web of Science ®Google Scholar
• Francis G, Kappos L, O'Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler 2013. [Epub ahead of print]
   Web of Science ®Google Scholar
• Henault D, Galleguillos L, Moore C, et al. Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Neurology 2013;81(20):1768-72
   PubMed Web of Science ®Google Scholar
• Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323(2):469-76
   PubMed Web of Science ®Google Scholar
• Anthony DC, Sibson NR, Losey P, et al. Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model. Neuropharmacology 2014(79C):534-41
   PubMedGoogle Scholar
• Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008;274(1-2):13-17
   PubMed Web of Science ®Google Scholar
• Birgbauer E, Chun J. New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 2006;63(23):2695-701
   PubMed Web of Science ®Google Scholar
• Herr DR, Chun J. Effects of LPA and SIP on the nervous system and implications for their involvement in disease. Curr Drug Targets 2007;8(1):155-67
   PubMed Web of Science ®Google Scholar
• Chun J, Weiner JA, Fukushima N, et al. Neurobiology of receptor-mediated lysophospholipid signaling - from the first lysophospholipid receptor to roles in nervous system function and development. Ann NY Acad Sci 2000;905:110-17
   PubMed Web of Science ®Google Scholar
• Miron VE, Jung CG, Kim HJ, et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63(1):61-71
   PubMed Web of Science ®Google Scholar
• Barske C, Osinde M, Mir AK, et al. FTY720 (fingolimod) enhances the number of progenitor & mature oligodendrocytes. Neurology 2007;68(12):A397-A97
   Web of Science ®Google Scholar
• Coelho RP, Payne SG, Bittman R, et al. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007;323(2):626-35
   PubMed Web of Science ®Google Scholar
• Mullershausen F, Craveiro LM, Shin Y, et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007;102(4):1151-61
   PubMed Web of Science ®Google Scholar
• van Doorn R, Nijland PG, Dekker N, et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol 2012;124(3):397-410
   PubMed Web of Science ®Google Scholar
• Foster CA, Mechtcheriakova D, Storch MK, et al. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol 2009;19(2):254-66
   PubMed Web of Science ®Google Scholar
• Balatoni B, Storch MK, Swoboda EM, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007;74(5):307-16
   PubMed Web of Science ®Google Scholar
• Al-Izki GPS, Baker D, Giouannoni G. Control of chronic relapsing progressive EAE with fingolimod. Neurology 2008;70(11):A29-9
   Web of Science ®Google Scholar
• Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011;108(2):751-6
   PubMed Web of Science ®Google Scholar
• Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I-KACh. Am J Transplant 2005;5(3):529-36
   PubMed Web of Science ®Google Scholar
• Koyrakh L, Lujan R, Colon J, et al. Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J Neurosci 2005;25(49):11468-78
   PubMed Web of Science ®Google Scholar
• Liu W, Zi M, Tsui H, et al. A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Circ Heart Fail 2013;6(4):833-44
   PubMed Web of Science ®Google Scholar
• Singer II, Tian M, Wickham LA, et al. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol 2005;175(11):7151-61
   PubMed Web of Science ®Google Scholar
• Chae SS, Proia RL, Hla T. Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat 2004;73(1-2):141-50
   PubMed Web of Science ®Google Scholar
• Guo Y, Singleton PA, Rowshan A, et al. Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. Mol Cell Proteomics 2007;6(4):689-96
   PubMed Web of Science ®Google Scholar
• McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 2004;92(6):1075-85
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 2006;6(3):244-50
   PubMed Web of Science ®Google Scholar
• Khatri B, Barkhof F, Comi G, et al. 24-month efficacy and safety outcomes from the TRANSFORMS extension study of oral fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis. Neurology 2010;74(9):A239-A39
   PubMed Web of Science ®Google Scholar
• Collins W, Cohen J, O’Connor P, et al. Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 1 and 3 studies. Mult Scler 2010;16(Suppl 10):S295
   Google Scholar
• Wu K, Mercier F, David OJ, et al. Population pharmacokinetics of fingolimod phosphate in healthy participants. J Clin Pharmacol 2012;52(7):1054-68
   PubMed Web of Science ®Google Scholar
• Singer B, Ross AP, Tobias K. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis. Int J Clin Pract 2011;65(8):887-95
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J Clin Pharmacol 2004;44(5):532-7
   PubMed Web of Science ®Google Scholar
• David OJ, Kovarik JM, Schmouder RL. Clinical pharmacokinetics of fingolimod. Clin Pharmacokinet 2012;51(1):15-28
   PubMed Web of Science ®Google Scholar
• Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002;13(4):1073-83
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Slade A, Voss B, et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther 2007;45(2):98-109
   PubMed Web of Science ®Google Scholar
• Gilenya (fingolimod hydrochloride tablets): US prescribing information. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2011/022527s002lbl.pdf [Cited 2013 Nov 9]
   Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf; EMAGfsopcoAfU
   Google Scholar
• FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf [Cited 2012]
   Google Scholar
• Zollinger M, Gschwind HP, Jin Y, et al. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. Drug Metab Dispos 2011;39(2):199-207
   PubMed Web of Science ®Google Scholar
• Jin Y, Zollinger M, Borell H, et al. CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a Novel treatment of relapsing multiple sclerosis. Drug Metab Dispos 2011;39(2):191-8
   PubMed Web of Science ®Google Scholar
• Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci 2011;11(5):492-7
   PubMed Web of Science ®Google Scholar
• O'Connor P, Comi G, Montalban X, et al. Oral fingolimod (FTY720) in multiple sclerosis two-year results of a phase II extension study. Neurology 2009;72(1):73-9
   PubMed Web of Science ®Google Scholar
• Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler 2010;16(2):197-207
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med 2010;362(5):387-401
   PubMed Web of Science ®Google Scholar
• Devonshire V, Havrdova E, O’Connor P, et al. Fingolimod (FTY720) reduces the risk of 3-month confirmed disability progression: sub-group analysis from the 24-month FREEDOMS study in relapsing MS. 63rd Annual Meeting of the American Academy of Neurology Honolulu; Hawaii; 2011
   Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 2010;362(5):402-15
   PubMed Web of Science ®Google Scholar
• Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet neurol 2011;10(6):520-9
   PubMed Web of Science ®Google Scholar
• Miller D Cree B, Dalton C, et al. Study design and baseline characteristics of the informs study: fingolimod in patients with primary progressive multiple sclerosis. Neurology 2013;80(Meeting Abstracts 1):P07.116
   Google Scholar
• Kuehn BM. FDA notes rare infection in patient who took fingolimod for MS. JAMA-J Am Med Assoc 2013;310(16):1666-6
   Web of Science ®Google Scholar
• EMA. 2012. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/04/WC500125689.pdf EEMAqaaotroGdrnEEHCA
   Google Scholar
• Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm; FFdscrrfcmauomsdGfF
   Google Scholar
• Fazekas F, Bajenaru O, Berger T, et al. How does fingolimod (gilenya(R)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis? Front Neurol 2013;4:10
   PubMedGoogle Scholar
• Crespo C, Izquierdo G, Garcia-Ruiz A, et al. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis. Neurologia 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Brandes DW, Raimundo K, Agashivala N, Kim E. Implications of real-world adherence on cost-effectiveness analysis in multiple sclerosis. J Med Econ 2013;16(4):547-51
   PubMedGoogle Scholar
• Bergvall N, Tambour M, Henriksson F, Fredrikson S. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing-remitting multiple sclerosis in Sweden. J Med Econ 2013;16(3):349-57
   PubMedGoogle Scholar
• Agashivala N, Kim E. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. Clin Ther 2012;34(7):1583-90
   PubMed Web of Science ®Google Scholar
• Heisen M, Treur MJ, van der Hel WS, et al. Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing-remitting multiple sclerosis in the Netherlands. J Med Econ 2012;15(6):1149-58
   PubMedGoogle Scholar
• O'Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ 2011;14(5):617-27
   PubMedGoogle Scholar
• Lee S, Baxter DC, Limone B, et al. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States. J Med Econ 2012;15(6):1088-96
   PubMedGoogle Scholar
• Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 2012;18(11):1640-3
   PubMed Web of Science ®Google Scholar
• Buzzard KA, Broadley SA, Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci 2012;13(10):12665-709
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Tsuji T, Watanabe S, et al. Efficacy of combination treatment with fingolimod (FTY720) plus pathogenic autoantigen in a glucose-6-phosphate isomerase peptide (GPI325-339)-induced arthritis mouse model. Biol Pharm Bull 2013;36(11):1739-46
   PubMed Web of Science ®Google Scholar
• Sorensen SD, Nicole O, Peavy RD, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003;64(5):1199-209
   PubMed Web of Science ®Google Scholar
• Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008;65(17):2702-20
   PubMed Web of Science ®Google Scholar
• Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005;50(4):427-34
   PubMed Web of Science ®Google Scholar
• Cannon RE, Peart JC, Hawkins BT, et al. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc Natl Acad Sci USA 2012;109(39):15930-5
   PubMed Web of Science ®Google Scholar